Advertisement


Anand P. Jillella, MD, on Acute Promyelocytic Leukemia: A Simplified Patient Care Strategy to Decrease Early Deaths

2022 ASH Annual Meeting and Exposition

Advertisement

Anand P. Jillella, MD, of Georgia Cancer Center at Augusta University, discusses results from the ECOG-ACRIN EA9131 Trial, which showed that using a simplified treatment algorithm and management recommendations made by a group of specialists, resulted in a dramatic improvement in 1-year survival of patients with acute promyelocytic leukemia (Abstract 421).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Acute promyelocytic leukemia is a highly aggressive but very curable leukemia. The current standard of care is all-trans retinoic acid and arsenic trioxide with or without chemotherapy. In clinical trials, about 95% to 98% of patients are cured. The induction death or early death, which is death within the first 30 days after diagnosis, is under 5%, and the relapse rate is less than 2%. So virtually everyone who survives induction is cured of their leukemia. However, that is not the case in the general population because in clinical trials the patients are usually younger and do not have any comorbid conditions. Whereas in the general population, you have older patients who might have other health issues. About 30% of patients do not survive induction or die during the first month after diagnosis. The one-year survival among all comers is about 60% to 70%. The only way to decrease survival among the general population is to decrease early deaths. The purpose of the ECOG-ACRIN 9131 trial was to decrease the induction mortality from an estimated 30% to less than 15%. At the Medical College of Georgia, in Augusta, Georgia, we recognized this as a problem way back in 2009. We evaluated our own experience and realized that 37% of our patients died within the first month after diagnosis. So we critically analyzed the problem and came up with a plan to decrease early deaths. Number one, we wrote a treatment algorithm or an operating procedure, which is a simplified procedure that tells you exactly how you have to manage the patient and the complications. The second thing is it is a rare disease, so we set up a panel of four experts. If there was a patient with APL in the community, the community oncologist would call one of the experts. The expert and the community oncologist would determine a consensus treatment plan, and the patient would be treated locally in the community but with ongoing communication with the APL expert. In this pilot trial, we accrued 120 patients. We had an early death rate of 8.5%. We used a similar model in the ECOG-ACRIN 9131 trial. We used the same algorithm. We set up seven APL experts who were available 24/7, and we rolled it out nationwide. There were absolutely no exclusion criteria. Elderly patients or patients with other health issues were recruited into the trial. A total of 200 patients were accrued, and we had seven deaths, which is an early death rate of 3.5%. As best as I know, this is the only proven concept that decreases early deaths in APL. This concept has also been proven in Latin America. The next steps would be to find a way to scale this and find a sustainable way to implement this nationwide.

Related Videos

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, on Mantle Cell Lymphoma: New Findings on Glofitamab Monotherapy

Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).

Leukemia
Issues in Oncology

Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends

Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute myeloid leukemia (AML). Between 2000 and 2019, AML mortality was the highest in Whites and the lowest in American Indians or Alaska Natives. The highest rate of increase in mortality was seen in Asians or Pacific Islanders. Dr. Al Armashi talks about the many variables that might contribute to these inequalities (Abstract 600).

Lymphoma

Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling

Alex F. Herrera, MD, of the City of Hope National Medical Center, discusses results from the POLARIX study, which showed that circulating tumor DNA (ctDNA) analysis has prognostic value for patients with previously untreated diffuse large B-cell lymphoma. Patients who did not achieve 2.5 or greater log-fold change and/or did not have ctDNA clearance following one cycle of polatuzumab vedotin along with rituximab, cyclophosphamide, doxorubicin, and prednisone had inferior outcomes than those who did. Early changes in ctDNA levels may be of use in risk-adapted trial designs to identify patients in need of alternative treatment. (Abstract 542).

Lymphoma

Eva Hoster, PhD, on Mantle Cell Lymphoma: Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance

Eva Hoster, PhD, of Munich University, discusses results from the European MCL Elderly Trial, which confirmed the strong efficacy of rituximab maintenance in minimal residual disease (MRD)-negative patients with mantle cell lymphoma (MCL) after induction. Omitting maintenance based on MRD-negativity is thus discouraged. Considering the short time to progression, more effective treatment strategies should be explored in MRD-positive patients to improve long-term prognosis (Abstract 544).

Leukemia
Lymphoma

Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).

Advertisement

Advertisement




Advertisement